On May 13, 2013, writes the Indian newspaper The Hindu, Indian pharmaceutical manufacturer Ranbaxy pleaded guilty to seven felonies relating to drug manufacturing fraud and agreed to cough up $500 million to settle the case brought by the U.S. Department of Justice (DoJ) after eight years of investigation. The vast evidence in the case included inspection reports compiled after multiple US FDA visits to Ranbaxy plants in India — in Paonta Sahib, Himachal Pradesh, and Dewas, Madhya Pradesh. Now two more major Indian pharmaceutical companies are coming under legal scrutiny.